Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78).
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78). · pmid:30291013
In the 32-week HARMONY 7 comparison, once-daily liraglutide lowered HbA1c more than once-weekly albiglutide (-0.99% against -0.78%); albiglutide caused more injection-site reactions and fewer gastrointestinal events. · pmid:24703047
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Established100%
Proportion of the 2 claims about Albiglutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Albiglutide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. · pmid 24703047 · 2014
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. · pmid 30291013 · 2018
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.